Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix

Vascular Closure Device Preserves the Femoral Artery

By HospiMedica International staff writers
Posted on 28 Feb 2013
Print article
Image: The Vascade Vascular Closure System (VCS) (Photo courtesy of Cardiva Medical).
Image: The Vascade Vascular Closure System (VCS) (Photo courtesy of Cardiva Medical).
An innovative extravascular device facilitates entry site closure in patients undergoing percutaneous procedures through the femoral artery.

The Vascade Vascular Closure System (VCS) utilizes a unique delivery system based on a proprietary collapsible disc technology made of a biconvex low-profile nitinol, which provides temporary hemostasis during the procedure, eliminating the need for an intravascular component. Secure and rapid hemostasis is achieved by the deployment of a thrombogenic, resorbable collagen hemostatic coating patch, which accelerates coagulation at the arteriotomy site in the femoral artery by expanding approximately 13 times in volume, thus ensuring that the residual tissue tract is sufficiently filled and provides mechanical hemostasis.

The VCS is indicated for femoral arterial access site closure while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures using a procedural sheath. The simple-to-use technique avoids the need for sheath exchange or added complexity, enabling deployment in as little as 30 seconds. The Vascade VCS is a product of Cardiva Medical (Sunnyvale, CA, USA), and has been approved by the US Food and Drug Administration (FDA).

“Vascade is a new generation of extravascular closure technology that offers significant advantages over conventional closure devices and manual compression,” said Frank Zidar, MD, of the Heart Hospital of Austin (TX, USA). “I am excited to be able to provide Vascade to my patients and to integrate it into my practice.”

The safety and effectiveness of Vascade VCS was evaluated in 420 patients across 21 clinical sites (up to 30 days post diagnostic or interventional procedures), that showed that the system is more effective than manual compression for mean time for hemostasis (TTH) and mean time to ambulation (TTA), and with fewer complications.

Related Links:

Cardiva Medical



Print article
Barco
Fluke Biomedical

Channels

Critical Care

view channel
Image: The BioMonitor 2-AF insertable cardiac remote monitor (Photo courtesy of Biotronik).

Insertable Cardiac Monitor Helps Detect Infrequent Arrhythmias

A new remote cardiac monitor provides physicians with the ability to accurately detect and diagnose atrial fibrillation (AF), ventricular tachycardia (VT), and syncope. The Biotronik (Berlin, Germany)... Read more

Women's Health

view channel

Flu Shot During Pregnancy May Halve Stillbirth Risk

A new study suggests that seasonal trivalent influenza vaccination (TIV) during pregnancy is associated with a significant reduction in stillbirths. Researchers at the University of Western Australia (UWA; Crawley, Australia) and Emory University (Atlanta, GA, USA) conducted a large, population-based study to evaluate... Read more

Hospital News

view channel

Mikkeli Central Hospital to Undergo Major Modernization

The European Investment Bank (Luxemburg; EIB) has provided a long-term loan of € 55 million to the South Savo Social and Health Care Joint Authority to renovate and extend the Central Hospital campus in Mikkeli (Finland). The campus, situated in the center of the 55,000 municipality, will undergo a renovation and extension... Read more

Business

view channel

Lightbeam Health Solutions Completes Acquisition of Browsersoft

Lightbeam (Irving, TX, USA) has bought Browsersoft (Shawnee Mission, KS, USA), a privately held health information exchange (HIE) solution provider for healthcare systems. The Browersoft OpenHRE solution enables healthcare communities to exchange data from disparate systems, thus enabling providers to have the most comprehensive,... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.